Coherus Biosciences Stock Probability Of Bankruptcy
| CHRS Stock | USD 1.22 0.04 3.17% |
Coherus | Probability Of Bankruptcy |
Coherus BioSciences Company probability of financial unrest Analysis
Coherus BioSciences' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Coherus BioSciences Probability Of Bankruptcy | Over 71% |
Most of Coherus BioSciences' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coherus BioSciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Coherus BioSciences probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Coherus BioSciences odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Coherus BioSciences financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coherus BioSciences. If investors know Coherus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coherus BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.09) | Revenue Per Share 2.678 | Quarterly Revenue Growth (0.05) | Return On Assets (0.14) |
The market value of Coherus BioSciences is measured differently than its book value, which is the value of Coherus that is recorded on the company's balance sheet. Investors also form their own opinion of Coherus BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Coherus BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coherus BioSciences' market value can be influenced by many factors that don't directly affect Coherus BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coherus BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Coherus BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coherus BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Coherus Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Coherus BioSciences is extremely important. It helps to project a fair market value of Coherus Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Coherus BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Coherus BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Coherus BioSciences' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Coherus BioSciences has a Probability Of Bankruptcy of 71%. This is 64.01% higher than that of the Biotechnology sector and 29.47% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 78.26% lower than that of the firm.
Coherus Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coherus BioSciences' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics of similar companies.Coherus BioSciences is currently under evaluation in probability of bankruptcy category among its peers.
Coherus BioSciences Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | 0.22 | 0.16 | (0.45) | (0.68) | (0.38) | (0.4) | |
| Asset Turnover | 0.87 | 0.57 | 0.48 | 0.44 | 0.41 | 0.29 | |
| Gross Profit Margin | 0.95 | 0.92 | 0.82 | 0.67 | 0.37 | 0.39 | |
| Net Debt | 718K | (137.1M) | (8.9M) | 407.5M | 378.0M | 396.8M | |
| Total Current Liabilities | 115.0M | 81.5M | 79.0M | 54.5M | 331.8M | 348.4M | |
| Non Current Liabilities Total | 303.7M | 479.1M | 502.6M | 563.8M | 491.3M | 288.9M | |
| Total Assets | 408.9M | 841.6M | 679.3M | 480.8M | 629.6M | 362.5M | |
| Total Current Assets | 374.7M | 790.4M | 633.5M | 416.7M | 475.6M | 311.1M | |
| Total Cash From Operating Activities | 28.4M | 154.1M | (37.4M) | (241.1M) | (174.9M) | (166.1M) |
Coherus Fundamentals
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 312.75 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 70.09 % | ||||
| Number Of Shares Shorted | 33.04 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.48 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | (58.4 M) | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Short Ratio | 12.34 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 235 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 145.17 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
| Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.